KOSPIBiotech & Pharma001060

Jw Pharmaceutical

₩26,800▼ 1.29%2026-10-02 close

Market Cap

₩622.9B

Turnover

₩600M

Volume

20,000 shares

Shares out.

23.3M

PER

6.6×

PBR

1.6×

EPS

₩4,186

Dividend Yield

2.36%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩650 per share · Prices as of the 2026-10-02 close

Report overview

Original Drug Growth Amid Compliance Risk

JW Pharmaceutical has improved profitability through original prescription drugs such as the Livalo family and Hemlibra, while still facing a sales suspension issue and an early-stage new drug pipeline.

1
2025 annual revenue reached KRW 775.3 billion with operating profit of KRW 94.5 billion, lifting the operating margin to 12.2% from 11.5% a year earlier.
2
In Q2 2025 the company posted an operating profit but a net loss attributable to owners, before returning to net profit from Q3 onward, showing quarter-to-quarter volatility.
3
As a follow-up administrative sanction tied to a past rebate case, 31 drug items were subject to a three-month sales suspension from May 6 to August 5.
4
The gout drug candidate epaminurad demonstrated statistically significant superiority over the standard treatment in a Phase 3 trial.
5
The company has licensed in domestic exclusive rights to a GLP-1 obesity drug from a Chinese firm, diversifying its pipeline.

Business structure

JW Pharmaceutical is a leading Korean pharmaceutical company operating in prescription drugs (ETC), IV fluids, and over-the-counter (OTC) products. Prescription drugs account for the bulk of sales, with ETC representing close to 80% of consolidated revenue in the most recent full year and first half.

Within that segment, the Livalo family of dyslipidemia treatments (Livalo, Livalo-Zet, Livalo-V, etc.) has steadily expanded its share, recently exceeding 20% of half-year revenue. Hemlibra, a hemophilia A treatment, is one of the fastest-growing original drugs, aided by expanded insurance coverage.

The IV fluids segment, anchored by the nutritional solution Winuf and enteral nutrition product Encover, maintains roughly a 30%-plus share of total revenue. The OTC segment, including the eye-care brand Friends and the wound-care band Himom, is comparatively smaller in scale.

On the R&D side, the company holds a clinical-stage pipeline including the gout treatment epaminurad, the STAT3-targeting anticancer candidate JW2286, and the hair-loss candidate JW0061, and has recently expanded its pipeline further by signing an exclusive domestic license-in deal for a GLP-1 obesity drug from a Chinese pharmaceutical company.

Competitively, the company contends with major domestic peers such as Yuhan Corporation, Hanmi Pharm, GC Biopharma, and Chong Kun Dang in the prescription market, while maintaining licensing and distribution partnerships with overseas originators for its original drug lineup.

Earnings trend

Quarterly revenue · Operating profit

₩191.1B₩25B25Q2₩200B₩32B25Q3₩198.9B₩15.5B25Q4₩199.9B₩33.6B26Q1₩222B₩33.3B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩684.4B₩63B2022₩748.5B₩100.3B2023₩719.4B₩82.5B2024₩775.3B₩94.5B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩191.1B	₩25B	13.1%
2025Q3	₩200B	₩32B	16.0%
2025Q4	₩198.9B	₩15.5B	7.8%
2026Q1	₩199.9B	₩33.6B	16.8%
2026Q2	₩222B	₩33.3B	15.0%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩684.4B	₩63B	₩31.9B	9.2%	13.3%	178.2%
2023	₩748.5B	₩100.3B	₩37B	13.4%	13.9%	143.0%
2024	₩719.4B	₩82.5B	₩65B	11.5%	19.7%	83.5%
2025	₩775.3B	₩94.5B	₩61.5B	12.2%	16.7%	63.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

In 2025, consolidated revenue reached KRW 775.3 billion with operating profit of KRW 94.5 billion (12.2% margin) and net profit attributable to owners of KRW 61.5 billion.

Compared with 2024 revenue of KRW 719.4 billion, operating profit of KRW 82.5 billion (11.5% margin), and net profit of KRW 65.0 billion, both revenue and operating profit grew while net profit slipped slightly.

In 2023, revenue was KRW 748.5 billion with an operating margin of 13.4%, the highest in the four-year window, though net profit was comparatively lower at KRW 37.0 billion, while 2022 was the weakest margin year with revenue of KRW 684.4 billion, operating profit of KRW 63.0 billion (9.2% margin), and net profit of KRW 31.9 billion.

Overall, revenue has trended steadily higher over the past four years, and the operating margin has improved from around 9% in 2022 to roughly 12% in 2025.

On a quarterly basis, Q2 2025 revenue was KRW 191.1 billion with operating profit of KRW 25.0 billion, a solid operating result, yet the company posted a net loss attributable to owners of KRW 1.9 billion, highlighting a gap between operating and bottom-line performance.

Net profit turned positive again in Q3 2025 (revenue KRW 200.0 billion, operating profit KRW 32.0 billion, net profit KRW 30.6 billion) and Q4 2025 (revenue KRW 198.9 billion, operating profit KRW 15.5 billion, net profit KRW 15.3 billion), continuing through Q1 2026 (revenue KRW 199.9 billion, operating profit KRW 33.6 billion, net profit KRW 27.5 billion) and Q2 2026 (revenue KRW 222.0 billion, operating profit KRW 33.3 billion, net profit KRW 27.9 billion).

The sum of net profit attributable to owners over the most recent four quarters (Q3 2025 through Q2 2026) is roughly KRW 101.3 billion, already exceeding the full-year 2025 net profit figure.

On the balance sheet, the debt ratio has also improved, falling from 178.2% in 2022 to 63.9% in 2025, indicating stronger capital stability.

Industry analysis

Korea's pharma and biotech sector is seen as passing through a phase of relatively subdued investor attention as capital concentrates on large-cap growth sectors such as semiconductors and artificial intelligence.

Within this environment, JW Pharmaceutical is regarded as having a degree of defensiveness thanks to its stable original prescription drugs and IV fluids business, which generate consistent cash flow.

In the atopic dermatitis treatment market, competition among IL-4/IL-13 class biologics is intensifying, with new entrants such as lebrikizumab (Ebglyss) targeting IL-13 signaling to differentiate from existing therapies, while JW Pharmaceutical is separately developing an atopic dermatitis candidate targeting the JAK-STAT pathway.

In the gout treatment market, where febuxostat serves as the standard of care, JW Pharmaceutical's epaminurad demonstrated superiority over the standard treatment in a Phase 3 trial, signaling a potential shift in the competitive landscape.

The obesity drug market is expanding rapidly on the back of the global spread of GLP-1 class medicines, and JW Pharmaceutical has sought to participate in this trend by securing domestic exclusive rights to a related drug candidate from a Chinese company.

Overall, the company appears positioned between the stability of its traditional original drug business and an innovative drug pipeline that remains pre-commercial.

Outlook

With the three-month sales suspension on 31 items ending on August 5, the company sees the pace of resumed shipments and sales normalization for those products as a key focus for the second half.

However, industry observers note that some prescriptions may have shifted to competing products while inventories were depleted during the suspension, suggesting full sales recovery could take time even after normalization.

On the drug development front, the gout treatment epaminurad is being prepared for a domestic New Drug Application (NDA) targeted for 2027, with the process advancing under a pilot program for innovative new drug approval and review run by the Ministry of Food and Drug Safety.

The company also expects to pursue global licensing discussions in parallel. The STAT3-targeting anticancer candidate JW2286 and the hair-loss candidate JW0061 remain in early clinical stages, and whether meaningful data emerges is cited as a variable that could affect future corporate valuation.

Following the domestic exclusive licensing of the GLP-1 obesity drug, clinical development and commercialization timelines are expected to be disclosed progressively.

Taken together, the variables likely to shape the company's performance and share price trajectory in the second half and beyond can be summarized into three threads: the speed of sales recovery for the suspended items, whether growth in the Livalo family, Hemlibra, and IV fluids continues, and progress in the new drug pipeline.

Valuation

PER

6.6×

PBR

1.6×

ROE

27.6%

EPS

₩4,186

BPS

₩16,967

Dividend per share

₩650

With net profit over the most recent four quarters already exceeding the full-year figure, the market appears to have priced in some of this earnings recovery.

The share price relative to net assets sits in a range that reflects a certain premium versus its own historical levels, which can be interpreted as a combination of growth in original drugs and expectations tied to the new drug pipeline.

Dividends have been paid annually, though the yield itself is regarded as relatively low compared with the industry average.

Given persistent non-operating uncertainties such as the sales suspension and rebate-related compliance issues, market assessment of the quality and sustainability of earnings may continue to shift depending on future quarterly disclosures and pipeline progress.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Margin Improvement Led by Original Drugs

The revenue share of original prescription drugs such as the Livalo family and Hemlibra has steadily expanded, lifting the operating margin from 9.2% in 2022 to 12.2% in 2025. This margin improvement is attributed to a portfolio shift toward higher-margin original products rather than lower-margin distributed items.

Hemlibra stands out as a case where quarterly sales grew rapidly following expanded insurance coverage. If this structural improvement continues, the company's underlying profitability could strengthen further.

Phase 3 Success for Gout Drug Candidate

The gout treatment candidate epaminurad demonstrated statistical superiority for its lead dose over the existing standard treatment in a multinational Phase 3 trial.

This marks a case where an in-house developed drug candidate has moved close to commercialization, with the process now advancing toward a targeted domestic NDA filing in 2027.

Its selection for a pilot program under the Ministry of Food and Drug Safety's innovative drug approval and review scheme is also cited as a positive factor for development speed. A successful approval combined with global licensing could open new revenue streams from drug sales and royalties.

Pipeline Diversification

The clinical-stage pipeline, including the STAT3-targeting anticancer candidate JW2286 and the hair-loss candidate JW0061, is expanding into areas such as oncology, metabolic disease, and regenerative medicine.

The company has also entered the growing obesity drug market by licensing in domestic exclusive rights to a GLP-1 class obesity treatment from a Chinese firm.

While many of these assets remain early-stage, spreading the pipeline across multiple therapeutic areas can help diversify the risk of any single drug candidate's failure. Accumulation of meaningful clinical data could open the door to further licensing discussions.

Bear factors

Compliance Overhang from Sales Suspension

Following an appellate court ruling on a rebate case dating to before 2018, 31 items were subject to a three-month sales suspension, with those items' prior-year sales of KRW 53.5 billion representing 6.91% of total revenue.

While the company has stated the annual impact would be limited, some prescriptions may have shifted to competitors' products where inventory ran out during the suspension.

How quickly market share can be recovered after the suspension ends remains a challenge, and the pace of restoring market confidence in compliance practices also warrants monitoring.

Quarterly Earnings Volatility

In Q2 2025, the company posted an operating profit of KRW 25.0 billion yet still recorded a net loss attributable to owners of KRW 1.9 billion, illustrating a divergence between operating and net results. This shows that non-operating factors can significantly sway a given quarter's bottom line.

Q4 2025 operating profit of KRW 15.5 billion was also notably lower than Q3 2025's KRW 32.0 billion or Q1 2026's KRW 33.6 billion, reflecting considerable quarter-to-quarter variance that makes it difficult to draw firm trend conclusions from any single quarter.

Execution Risk in Early-Stage Pipeline

JW0061 is still preparing to enter Phase 1 trials, and JW2286 also remains at an early clinical stage, meaning substantial time and further clinical success are needed before commercialization.

The GLP-1 obesity drug is likewise at an early stage following the domestic exclusive license, leaving uncertainty around development and approval timelines. Even epaminurad, despite its Phase 3 success, still must go through the subsequent stages of regulatory approval and potential global licensing negotiations.

A fundamental constraint remains that new drug development carries an inherent risk of failure or delay at any clinical stage.

Risk factors

Policy and Regulatory Risk

Drug price cuts or changes to reimbursement criteria could directly affect the profitability of core original products such as the Livalo family and Hemlibra.

Separately from criminal proceedings, a Fair Trade Commission fine and related administrative litigation over the rebate matter are reportedly still ongoing, meaning additional sanctions or legal risk have not been fully resolved.

Administrative penalties such as the sales suspension represent a structural risk that could recur if similar compliance issues arise again.

Competitive Intensity Risk

Competition among IL-4/IL-13 class biologics in the atopic dermatitis market is intensifying, meaning that even if JW Pharmaceutical's JAK-STAT-targeting candidate reaches commercialization, securing market position may not be straightforward.

Competition from the standard treatment and other developers is also expected in the gout treatment market. In the obesity drug market, large global pharmaceutical companies have already established a strong position, so a domestic exclusive license alone may offer limited competitive advantage as a later entrant.

Risk of Delayed Earnings Normalization

Even after the sales suspension ended, full sales recovery could take time if prescriptions for out-of-stock items shifted to competitors' products. There are also observations that sales and marketing efforts need to be strengthened in the second half to restore the prior scale of sales.

In addition, continued expansion of R&D spending could potentially slow the pace of operating margin improvement in the near term.

What to watch next

Early November 2026 (expected Q3 earnings release)
This is the point to check the pace of sales normalization for the 31 previously suspended items and whether overall revenue and operating margin have recovered.
Second half of 2026 through 2027
Progress on preparations for the domestic NDA filing for gout drug epaminurad and any advancement in global licensing discussions should be monitored.
From the second half of 2026 onward
It will be important to check whether concrete domestic clinical/development timelines emerge for the GLP-1 obesity drug, and whether progress updates are disclosed for early-stage pipeline assets such as JW2286 and JW0061.
At each quarterly earnings disclosure
It is worth tracking whether sales growth continues for key original product lines such as the Livalo family, Hemlibra, and IV fluids, and whether quarter-to-quarter net profit volatility eases.

Overall view

JW Pharmaceutical is a company that has lifted both revenue and operating margin from 2022 through 2025, anchored by original prescription drugs such as the Livalo family, Hemlibra, and IV fluids.

At the same time, quarterly earnings volatility persists, as seen in the net loss recorded in Q2 2025, and the 31-item sales suspension stemming from a pre-2018 rebate case shows that compliance risk has not been fully resolved.

On the pipeline side, the gout treatment epaminurad, having achieved a successful Phase 3 result and targeting approval in 2027, stands as the most advanced candidate, while the STAT3 anticancer drug JW2286, hair-loss candidate JW0061, and the licensed-in GLP-1 obesity drug remain at earlier stages.

Going into the second half and beyond, three factors are likely to shape the company's fundamentals: the pace of sales normalization for the suspended items, whether growth in the original product lines continues, and further progress in the clinical pipeline.

As all of these remain unresolved future events, continued monitoring of quarterly disclosures and clinical/regulatory news is warranted before forming any investment judgment. This report is for informational purposes only and does not constitute a buy or sell recommendation.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.